The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib

Cover Page

Cite item

Full Text

Abstract

The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib was developed by the experts of the Russian Association of Endocrinologists and the Russian Society of Clinical Oncology. The consensus contains recommendation on risk assessment, prophylaxis and correction of hyperglycemia regarding the baseline metabolic status of the patients.

About the authors

Natalya V. Mazurina

Endocrinology Research Centre

Author for correspondence.
Email: natalyamazurina@mail.ru
ORCID iD: 0000-0001-8077-9381

D. Sci. (Med.)

Russian Federation, Moscow

Elena V. Artamonova

Blokhin National Medical Research Center of Oncology

Email: artamonovae@mail.ru
ORCID iD: 0000-0001-7728-9533

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Maria F. Beloyartseva

Blokhin National Medical Research Center of Oncology

Email: mfb1973@gmail.com
ORCID iD: 0000-0002-7897-3422

Cand. Sci. (Med.)

Russian Federation, Moscow

Ekaterina I. Volkova

Loginov Moscow Clinical Scientific Center

Email: volkowa_endocrinology@mail.ru
ORCID iD: 0000-0003-3717-1148

endocrinologist

Russian Federation, Moscow

Inna P. Ganshina

Blokhin National Medical Research Center of Oncology

Email: ganshinainna77@mail.ru
ORCID iD: 0000-0002-0105-9376

Cand. Sci. (Med.)

Russian Federation, Moscow

Ekaterina A. Troshina

Endocrinology Research Centre

Email: troshina@inbox.ru
ORCID iD: 0000-0002-8520-8702

D. Sci. (Med.), Prof., Corr. Memb. RAS

Russian Federation, Moscow

Sergey A. Tjulandin

Blokhin National Medical Research Center of Oncology

Email: clingen@mail.ru
ORCID iD: 0000-0001-9807-2229

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Viacheslav A. Chubenko

Saint Petersburg Clinical Scientific and Practical Center for Specialised Types of Medical Care (Oncological)

Email: vchubenko@me.com
ORCID iD: 0000-0001-6644-6687

Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

References

  1. Стенина М.Б., Жукова Л.Г., Королева И.А. и др. Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли. 2020; 10 (3s2). https://rosoncoweb.ru/standarts/RUSSCO/2020/2020-09.pdf [Stenina M.B., Zhukova L.G., Koroleva I.A. et al. Practical recommendations for drug treatment of breast cancer. Malignant Tumors. 2020; 10 (3s2). https://rosoncoweb.ru/standarts/RUSSCO/2020/2020-09.pdf (in Russian).]
  2. Семиглазова Т.Ю., Семиглазов В.В., Клименко В.В. и др. Применение алпелисиба для лечения HR+ HER2-метастатического рака молочной железы у пациентов с мутацией PIK3CA: результаты исследования SOLAR-1. Фарматека. 2020; 27 (7): 15–23. doi: 10.18565/pharmateca.2020.7.15-23 [Semiglazova T.Iu., Semiglazov V.V., Klimenko V.V. et al. Primenenie alpelisiba dlia lecheniia HR+ HER2-metastaticheskogo raka molochnoi zhelezy u patsientov s mutatsiei PIK3CA: rezul’taty issledovaniia SOLAR-1. Farmateka. 2020; 27 (7): 15–23. doi: 10.18565/pharmateca.2020.7.15-23 (in Russian).]
  3. Andre F, Ciruelos E, Rubovszky G et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380: 1929–40. doi: 10.1056/NEJMoa1813904
  4. Rugo HS, André F, Yamashita T et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol 2020; 31 (8): 1001–10. doi: 10.1016/j.annonc.2020.05.001
  5. Świderska E, Strycharz J, Wroblewski A et al. Role of PI3K/AKT Pathway in Insulin-Mediated Glucose Uptake. 2018. doi: 10.5772/intechopen.80402
  6. Дедов И.И., Шестаков М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2019; 22 (1S1): 1–144. doi: 10.14341/DM221S1 [Dedov I.I., Shestakova M.V., Mayorov A.Y. et al. Standards of specialized diabetes care. Diabetes mellitus. 2019; 22 (1S1): 1–144. doi: 10.14341/DM221S1 (in Russian).]
  7. Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Клинические рекомендации Российской ассоциации эндокринологов. Сахарный диабет 1 типа у взрослых. Сахарный диабет. 2020; 23 (S1). doi: 10.14341/DM23S1 [Dedov I.I., Shestakova M.V., Maiorov A.Iu. et al. Klinicheskie rekomendatsii Rossiiskoi assotsiatsii endokrinologov. Sakharnyi diabet 1 tipa u vzroslykh. Sakharnyi diabet. 2020; 23 (S1). doi: 10.14341/DM23S1 (in Russian).]
  8. Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Клинические рекомендации Российской ассоциации эндокринологов. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020; 23 (S2). doi: 10.14341/DM23S2 [Dedov I.I., Shestakova M.V., Maiorov A.Iu. et al. Klinicheskie rekomendatsii Rossiiskoi assotsiatsii endokrinologov. Sakharnyi diabet 2 tipa u vzroslykh. Sakharnyi diabet. 2020; 23 (S2). doi: 10.14341/DM23S2 (in Russian).]
  9. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42 (Suppl. 1): S13–S28. doi: 10.2337/dc19-S002
  10. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42 (Suppl. 1): S90–S102. doi: 10.2337/dc19-S009
  11. Classification of diabetes mellitus. World Health Organization, 2019. https://apps.who.int/iris/handle/10665/325182
  12. Davies MJ, D’Alessio DA, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61: 2461–98. doi: 10.1007/s00125-018-4729-5/
  13. Инструкция по медицинскому применению препарата Пикрэй ЛП-006279 от 19.06.2020. [Instructions for medical use of the drug Pikray LP-006279 dated 06/19/2020 (in Russian).]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Assessment of risk factors for the development of hyperglycemia prior to alpelisib initiation.

Download (88KB)
Indexing metadata
3. Fig. 2. Prevention and management of alpelisib-induced hyperglycemia.

Download (128KB)
Indexing metadata

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).